Inhaled fluticasone in acute severe asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN96658320

Enrollment

110

Registered

2007-07-12

Start date

2006-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute severe asthma, acute exacerbation of asthma Respiratory Asthma

Interventions

Baseline Measurements: Subjects, those who are randomised will be asked to perform baseline Peak Expiratory Flow (PEF) and Forced Expiratory Volume at one second (FEV1). Blood samples will be drawn f

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18 to 55 2. Asthma patients with Peak Expiratory Flow (PEF) and Forced Expiratory Volume in one second (FEV1) less than 50% of the predicted 3. Asthmatic for six months or more

Exclusion criteria

Exclusion criteria: 1. Underlying chronic lung disease 2. Fever more than 100.4°F 3. Smoker greater than five pack years 4. Patients with no legal representative or legal representative not willing to give consent 5. Life threatening asthma

Design outcomes

Primary

Measure	Time frame
FEV1 and PEF at 90 minutes and 180 minutes from the time of administering the drug.	—

Secondary

Measure	Time frame
1. Symptom assessment, at 90 minutes and180 minutes from the time of administering the drug 2. Adverse effect of fluticasone at 90 minutes and180 minutes from the time of administering the drug	—

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026